Prognostic gene signature and method for diffuse large b-cell lymphoma prognosis and treatment

A method of treating diffuse large B-cell lymphoma in a patient in need thereof, said method comprising:

• receiving gene expression values for at least ALDOC, ASIP, ATP8A1, CD1E, DUSP16, FAF1, FAM223A1FAM223B, GAREM, GNG8, LMO2, LPPR4, LY75, MAEL, PADI2, PDK1, PPP1R7, SCN1A, SLAMF1, SSTR2, TNFRSF9, USH2A, VEZF1, WDR91, ADRA2B, ECT2, ELOVL6, IGSF9, NEK3, PDK4, PES1, PUSL1, TADA2A, and ZMYND19 detected in a biological sample from the patient;
• determining a risk score for said patient based upon increased or decreased expression of each of said gene expression values as compared to a reference standard;
• and
• administering a therapeutic agent to said patient to treat said diffuse large B-cell lymphoma, wherein said therapeutic agent comprises a standard of care active agent when said risk score is low and wherein said therapeutic agent comprises an adjunctive chemotherapeutic, experimental therapy, and/or aggressive active agent against said diffuse large B-cell lymphoma when said risk score is high.

A system for diffuse large B-cell lymphoma prognosis and treatment in a patient in need thereof, said system comprising:

• user interface for receiving gene expression values for at least ALDOC, ASIP, ATP8A1, CD1E, DUSP16, FAF1, FAM223A1FAM223B, GAREM, GNG8, LMO2, LPPR4, LY75, MAEL, PADI2, PDK1, PPP1R7, SCN1A, SLAMF1, SSTR2, TNFRSF9, USH2A, VEZF1, and WDR91 in a biological sample from the patient to generate a first gene expression profile;
• computer readable memory to store said first gene expression profile;
• at least one database comprising a reference standard for each of the first set of genes;
• a processor with a computer-readable program code comprising instructions for comparing the first gene expression profile with the reference standard data correlating increased expression levels of said first set of genes with improvement in overall survival outcomes in the patient, and calculating a risk score;
• and
• an output for reporting a risk score for said patient.

A method for diffuse large B-cell lymphoma prognosis and treatment in a patient in need thereof, said method comprising:

• receiving gene expression values for at least ALDOC, ASIP, ATP8A1, CD1E, DUSP16, FAF1, FAM223A1FAM223B, GAREM, GNG8, LMO2, LPPR4, LY75, MAEL, PADI2, PDK1, PPP1R7, SCN1A, SLAMF1, SSTR2, TNFRSF9, USH2A, VEZF1, and WDR91 in a biological sample from the patient;
• generating a first gene expression profile;
• comparing the first gene expression profile with a reference standard data for each of said genes;
• correlating increased expression levels of said first set of genes with improvement in overall survival outcomes in the patient;
• and
• calculating a risk score predictive of overall survival for said patient.

A kit for diffuse large B-cell lymphoma prognosis and treatment in a patient in need thereof, said kit comprising:

• a plurality of probes each having binding specificity for a target gene in a gene panel comprising ALDOC, ASIP, ATP8A1, CD1E, DUSP16, FAF1, FAM223A1FAM223B, GAREM, GNG8, LMO2, LPPR4, LY75, MAEL, PADI2, PDK1, PPP1R7, SCN1A, SLAMF1, SSTR2, TNFRSF9, USH2A, VEZF1, WDR91, ADRA2B, ECT2, ELOVL6, IGSF9, NEK3, PDK4, PES1, PUSL1, TADA2A, and ZMYND19, or a gene product thereof;
• optional reagents and/or buffers;
• and
• instructions for mixing said probes with a biological sample obtained from said patient.